ESR1
methylation status |
||||||||||||
All
breast cancer cases |
Methylated
breast tumor |
Unmethylated
breast tumor |
||||||||||
Body
mass index |
ER+PR+/ |
ORc |
95% CId |
|
ER+PR+/ ER-PR- |
OR |
95% CI |
|
ER+PR+/ |
OR |
95% CI |
p for interaction |
BMId (<25kg/m2) |
86/37 |
1.00 |
reference |
40/15 |
1.00 |
reference |
46/22 |
1.00 |
reference |
0.019 |
||
BMI (25-29.9kg/m2) |
82/22 |
1.50 |
(0.81, 2.78) |
39/8 |
1.79 |
(0.68, 4.70) |
43/14 |
1.42 |
(0.64, 3.13) |
|||
BMI (≥30kg/m2) |
78/19 |
1.74 |
(0.92, 3.28) |
|
33/13 |
0.99 |
(0.41, 2.38) |
|
45/6 |
3.76 |
(1.39, 10.15) |
|
Supplemental Table 1: Age-adjusted odds ratios (ORs) and 95% confidence intervals
(CIs) for the association between postmenopausal body mass index (BMI) and
ER+PR+ breast cancer (vs. ER-PR- breast cancer) considering ESR1
methylation status of the tumor (methylated vs. unmethylated), the Long Island
Breast Cancer Study Project (1996-1997).